11. Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trialVaneja Velenik, Janja Ocvirk, Irena Oblak, Franc Anderluh, 2012, original scientific article Abstract: Preoperative capecitabine-based chemoradiotherapy (CRT) is feasible for the treatment of resectable locally advanced rectal cancer (LARC). To try to improve efficacy, we conducted a phase II studz in which the epidermal growth factor receptor-targeting monoclonal antibody cetuximab was added to capecitabine-based CRT. The results for long-term survival and for an analysis investigating the relationship between survival and patient and disease characteristics, including tumour KRAS mutation status, and surgery type, are presented. Patients with resectable LARC received capecitabine (1250mg/m2 twice daily, orally) for 2 weeks followed by cetuximab alone (400 mg/m2 for 1 week) and then with CRT (250 mg/m2/week) comprising capecitabine (825 mg/m2 twice daily) and radiotherapy to the small pelvis (45 Gz in 25 1.8-Gz fractions), five dazs a week for five weeks. Surgery was conducted six weeks following CRT, with post-operative chemotherapy with capecitabine (1250 mg/m2 twice daily for 14 days every 21 days) three weeks later. Forty-seven patients were enrolled and 37 underwent treatment. Twenty-eight of the patients (75.7%) had T3N+ disease. Thirty-six patients were evaluable for efficacy. The median follow-up time was 39.0 months (range 5.0-87.0). The three-year local control, disease-free survival, relapse-free survival and overall survival rates were 96.9% (95% CI 90.0-100), 72.2% (57.5-86.9), 74.3% (95% CI 59.8-88.8) and 68.1% (95% CI 36.7-99.4), respectively. There was no significant association between survival and gender, age, tumour location in the rectum, type of surgery, pathological T or N status, tumour regression grade or tumour KRAS mutation status, although sample sizes were small. Preoperative cetuximab plus capecitabine-based CRT was feasible in patients with resectable LARC and was associated with an impressive three-year local control rate. The use of tumour KRAS mutation status as a biomarker for the efficacy of cetuximab-based regimens in this setting requires further investigation. Published in DiRROS: 21.03.2024; Views: 100; Downloads: 35 Full text (332,74 KB) |
12. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer : a single institution retrospective analysisMartina Reberšek, Marko Boc, Petra Škerl, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Srdjan Novaković, Janja Ocvirk, 2011, original scientific article Keywords: rak (medicina), debelo črevo, danka, zdravljenje Published in DiRROS: 18.03.2024; Views: 94; Downloads: 36 Full text (461,04 KB) |
13. |
14. |
15. Cisplatin-induced non-convulsive posterior reversible encephalopathy syndrome in a 41-year-old woman with metastatic malignant melanomaJanja Ocvirk, Marko Boc, Martina Reberšek, Tanja Roš-Opaškar, 2009, original scientific article Abstract: Background. Cisplatin, a widely used antineoplastic agent usually induces peripheral neuropathy, but can rarely also complicate with encephalopathy, with or without seizures. Case report. We report a case of a young patient with metastatic malignant melanoma with signs and symptoms of cisplatin-induced non-convulsive posterior reversible encephalopaty syndrome. Within the days shortly after the first cycle of cisplatin based chemotherapy the patient suffered from nausea, vomitus, headache, severe pain at the site of sub-cutaneous metastases and confusion. She later experienced somnolence, cortical blindness and aphasia, but without epileptic seizures. Conclusions. Cisplatin is an effective chemotherapeutic drug but also very toxic one and physicians using it must also be aware of possible encephalopathy. Published in DiRROS: 08.03.2024; Views: 123; Downloads: 39 Full text (343,74 KB) |
16. |
17. |
18. Paratesticular adenocarcinoma : unusual presentation of metastasis of pancreatic cancerJanja Ocvirk, Boštjan Šeruga, 2007, short scientific article Abstract: Background. Metastatic paratesticular adenocarcinoma from the pancreatic cancer is very rare. To our knowledge, there are less than 20 cases published in the literature. Case report. We experienced a case of paratesticular adenocarcinoma from the primary pancreatic cancer. A 42-year-old man was presented with locoregionally advanced carcinoma of the tail of the pancreas with intraoperatively found liver metastases and with a tumour in the right hemi-scrotum. Ultrasound of the scrotum revealed a paratesticular tumour. A fine needle aspiration biopsy (FNAB) confirmed a poorly differentiated adenocarcinoma and it was in concordance with the diagnosis of the primary tumour. The patient started treatment with chemotherapy with gemcitabine. Unfortunately, he progressed one month later and the treatment was discontinued. Conclusions. Outcome in the adenocarcinoma of the pancreas is dismal. The only possible treatment option for metastatic disease is systemic therapy but the results are disappointing, as in the present case. Published in DiRROS: 19.02.2024; Views: 122; Downloads: 35 Full text (78,71 KB) |
19. Elektrokemoterapija pri lokalnem zdravljenju napredovalega melanomaGregor Serša, Zvonimir Rudolf, Marija Snežna Paulin-Košir, Janja Ocvirk, Maja Čemažar, Simona Kranjc Brezar, Breda Slekovec Kolar, Marko Snoj, 2007, published scientific conference contribution Published in DiRROS: 06.12.2023; Views: 206; Downloads: 58 Full text (779,60 KB) |
20. |